Company intelligence / Profile preview

Tallikut Pharmaceuticals, Inc.

California, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Tallikut Pharmaceuticals, Inc. is a private pharmaceutical company based in California, United States. Its lead drug candidate was Atreleuton (VIA-2291), a small molecule inhibitor of the enzyme five-lipoxygenase (5-LOX), developed for cardiovascular and inflammatory indications such as carotid stenosis and previously acute coronary syndrome. The most advanced clinical trial reached Phase II but the program has since been discontinued. There are no publicly disclosed active pipeline programs or recent clinical results as of early-2025.

Therapeutic areas: Cardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

picoplatin

Phase 2

Indications: Small cell lung cancer, Squamous cell carcinoma of head and neck, Colorectal cancer

Beyond the preview

Go deeper on Tallikut Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tallikut Pharmaceuticals, Inc..

Explore the full profile